<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SKELAXIN- metaxalone tablet </strong><br>Pfizer Laboratories Div Pfizer Inc<br></p></div>
<h1>SKELAXIN<span class="Sup">®</span><br>(Metaxalone) Tablets</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_eb6793bf-8658-46c8-9232-ce57f5494841"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">SKELAXIN<span class="Sup">®</span> (metaxalone) is available as an 800 mg oval, scored pink tablet.</p>
<p>Chemically, metaxalone is 5-[(3,5- dimethylphenoxy) methyl]-2-oxazolidinone. The empirical formula is C<span class="Sub">12</span>H<span class="Sub">15</span>NO<span class="Sub">3</span>, which corresponds to a molecular weight of 221.25. The structural formula is:</p>
<p><img alt="ChemStructure1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7a4163f2-c553-4d14-7e98-d14c5c7f772a&amp;name=skelaxin-01.jpg"></p>
<p>Metaxalone is a white to almost white, odorless crystalline powder freely soluble in chloroform, soluble in methanol and in 96% ethanol, but practically insoluble in ether or water. </p>
<p>Each tablet contains 800 mg metaxalone and the following inactive ingredients: alginic acid, ammonium calcium alginate, B-Rose Liquid, corn starch, and magnesium stearate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_89f638c3-eb67-4adf-b18d-5279b897ebc5"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_2453dc2a-1ffb-4a6c-8685-5ea7ef6d0028"></a><a name="section-2.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">The mechanism of action of metaxalone in humans has not been established, but may be due to general central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. Metaxalone has no direct action on the contractile mechanism of striated muscle, the motor end plate, or the nerve fiber.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_7829cc73-cf47-481b-8aaa-e5ae6bcf4be6"></a><a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">The pharmacokinetics of metaxalone have been evaluated in healthy adult volunteers after single dose administration of SKELAXIN under fasted and fed conditions at doses ranging from 400 mg to 800 mg. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e06c65ee-c7ba-410e-b82d-c9745cf99d9d"></a><a name="section-2.2.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Absorption</span></span></h3>
<p class="First">Peak plasma concentrations of metaxalone occur approximately 3 hours after a 400 mg oral dose under fasted conditions. Thereafter, metaxalone concentrations decline log-linearly with a terminal half-life of 9.0 ± 4.8 hours. Doubling the dose of SKELAXIN from 400 mg to 800 mg results in a roughly proportional increase in metaxalone exposure as indicated by peak plasma concentrations (C<span class="Sub">max</span>) and area under the curve (AUC). Dose proportionality at doses above 800 mg has not been studied. The absolute bioavailability of metaxalone is not known.</p>
<p>The single-dose pharmacokinetic parameters of metaxalone in two groups of healthy volunteers are shown in Table 1.</p>
<a name="id_0ece46d6-de29-453e-a112-f7be3383a56d"></a><table border="1">
<caption><span>Table 1: Mean (%CV) Metaxalone Pharmacokinetic Parameters</span></caption>
<col width="98*">
<col width="99*">
<col width="100*">
<col width="100*">
<col width="99*">
<col width="100*">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top">
<span class="Bold">Dose</span> (mg)</td>
<td class="Toprule" align="left" valign="top">
<span class="Bold">C<span class="Sub">max</span></span> (ng/mL)</td>
<td class="Toprule" align="left" valign="top">
<span class="Bold">T<span class="Sub">max</span></span> (h)</td>
<td class="Toprule" align="left" valign="top">
<span class="Bold">AUC<span class="Sub">∞</span></span> (ng•h/mL)</td>
<td class="Toprule" align="left" valign="top">
<span class="Bold">t<span class="Sub">½</span></span>(h)</td>
<td align="left" valign="top">
<span class="Bold">CL/F</span> (L/h)</td>
</tr>
<tr>
<td align="left" valign="top">400<span class="Sup">1</span>
</td>
<td align="left" valign="top">983 (53)</td>
<td align="left" valign="top">3.3 (35)</td>
<td align="left" valign="top">7479 (51)</td>
<td align="left" valign="top">9.0 (53)</td>
<td align="left" valign="top">68 (50)</td>
</tr>
<tr>
<td align="left" valign="top">800<span class="Sup">2</span>
</td>
<td align="left" valign="top">1816 (43)</td>
<td align="left" valign="top">3.0 (39)</td>
<td align="left" valign="top">15044 (46)</td>
<td align="left" valign="top">8.0 (58)</td>
<td align="left" valign="top">66 (51)</td>
</tr>
<tr class="Botrule Last"><td align="left" colspan="6" valign="top">
<span class="Sup">1</span>Subjects received 1x400 mg tablet under fasted conditions (N=42) <p class="First"><span class="Sup">2</span>Subjects received 2x400 mg tablets under fasted conditions (N=59)</p>
</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aa1f727d-6b52-497f-8ebe-1079b9cfd4a7"></a><a name="section-2.2.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Food Effects</span></span></h3>
<p class="First">A randomized, two-way, crossover study was conducted in 42 healthy volunteers (31 males, 11 females) administered one 400 mg SKELAXIN tablet under fasted conditions and following a standard high-fat breakfast. Subjects ranged in age from 18 to 48 years (mean age = 23.5 ± 5.7 years). Compared to fasted conditions, the presence of a high fat meal at the time of drug administration increased C<span class="Sub">max</span> by 177.5% and increased AUC (AUC<span class="Sub">0-t</span>, AUC<span class="Sub">∞</span>) by 123.5% and 115.4%, respectively. Time-to-peak concentration (T<span class="Sub">max</span>) was also delayed (4.3 h <span class="Italics">versus</span> 3.3 h) and terminal half-life was decreased (2.4 h <span class="Italics">versus</span> 9.0 h) under fed conditions compared to fasted. </p>
<p>In a second food effect study of similar design, two 400 mg SKELAXIN tablets (800 mg) were administered to healthy volunteers (N=59, 37 males, 22 females), ranging in age from 18-50 years (mean age = 25.6± 8.7 years). Compared to fasted conditions, the presence of a high fat meal at the time of drug administration increased C<span class="Sub">max</span> by 193.6% and increased AUC (AUC<span class="Sub">0-t</span>, AUC<span class="Sub">∞</span>) by 146.4% and 142.2%, respectively. Time-to-peak concentration (T<span class="Sub">max</span>) was also delayed (4.9 h <span class="Italics">versus</span> 3.0 h) and terminal half-life was decreased (4.2 h <span class="Italics">versus</span> 8.0 h) under fed conditions compared to fasted conditions. Similar food effect results were observed in the above study when one SKELAXIN 800 mg tablet was administered in place of two SKELAXIN 400 mg tablets. The increase in metaxalone exposure coinciding with a reduction in half-life may be attributed to more complete absorption of metaxalone in the presence of a high fat meal (Figure 1).</p>
<p><img alt="Graph1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7a4163f2-c553-4d14-7e98-d14c5c7f772a&amp;name=skelaxin-02.jpg"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bacf56e0-1eff-4d15-a7ba-7e400b28ff8a"></a><a name="section-2.2.3"></a><p></p>
<h3><span class="Bold"><span class="Italics">Distribution, Metabolism, and Excretion</span></span></h3>
<p class="First">Although plasma protein binding and absolute bioavailability of metaxalone are not known, the apparent volume of distribution (V/F ~ 800 L) and lipophilicity (log P = 2.42) of metaxalone suggest that the drug is extensively distributed in the tissues. Metaxalone is metabolized by the liver and excreted in the urine as unidentified metabolites.  Hepatic Cytochrome P450 enzymes play a role in the metabolism of metaxalone.  Specifically, CYP1A2, CYP2D6, CYP2E1, and CYP3A4 and, to a lesser extent, CYP2C8, CYP2C9, and CYP2C19 appear to metabolize metaxalone.</p>
<p>Metaxalone does not significantly inhibit major CYP enzymes such as CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4. Metaxalone does not significantly induce major CYP enzymes such as CYP1A2, CYP2B6, and CYP3A4<span class="Italics"> in vitro</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_90744675-01d9-418d-841b-cf115810e25f"></a><a name="section-2.2.4"></a><p></p>
<h3><span class="Bold"><span class="Italics">Pharmacokinetics in Special Populations</span></span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_92a27d70-9ba8-4e43-b3d4-40f5b2c54f57"></a><a name="section-2.2.4.1"></a><p></p>
<h4><span class="Italics">Age:</span></h4>
<p class="First">The effects of age on the pharmacokinetics of metaxalone were determined following single administration of two 400 mg tablets (800 mg) under fasted and fed conditions. The results were analyzed separately, as well as in combination with the results from three other studies. Using the combined data, the results indicate that the pharmacokinetics of metaxalone are significantly more affected by age under fasted conditions than under fed conditions, with bioavailability under fasted conditions increasing with age. </p>
<p> The bioavailability of metaxalone under fasted and fed conditions in three groups of healthy volunteers of varying age is shown in Table 2.</p>
<a name="id_1f189d96-08ea-46ec-93dc-34549daccb9b"></a><table border="1" width="0.000">
<caption><span>Table 2: Mean (%CV) Pharmacokinetic Parameters Following Single Administration of Two 400 mg SKELAXIN Tablets (800 mg) under Fasted and Fed Conditions </span></caption>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top"></td>
<td class="Toprule" align="center" colspan="2" valign="top"><span class="Bold">Younger Volunteers</span></td>
<td align="center" colspan="4" valign="top"><span class="Bold">Older Volunteers</span></td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Bold">Age</span> (years)</td>
<td align="center" colspan="2" valign="top">25.6 ± 8.7</td>
<td align="center" colspan="2" valign="top">39.3 ± 10.8</td>
<td align="center" colspan="2" valign="top">71.5 ± 5.0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">N</span></td>
<td align="center" colspan="2" valign="top">59</td>
<td align="center" colspan="2" valign="top">21</td>
<td align="center" colspan="2" valign="top">23</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Food</span></td>
<td align="center" valign="top">Fasted</td>
<td align="center" valign="top">Fed</td>
<td align="center" valign="top">Fasted</td>
<td align="center" valign="top">Fed</td>
<td align="center" valign="top">Fasted</td>
<td align="center" valign="top">Fed</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Bold">C<span class="Sub">max</span></span> (ng/mL)</td>
<td align="center" valign="top">1816 <br>(43)</td>
<td align="center" valign="top">3510 <br>(41)</td>
<td align="center" valign="top">2719 <br>(46)</td>
<td align="center" valign="top">2915 <br>(55)</td>
<td align="center" valign="top">3168 <br>(43)</td>
<td align="center" valign="top">3680 <br>(59)</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Bold">T<span class="Sub">max</span></span> (h)</td>
<td align="center" valign="top">3.0 <br>(39)</td>
<td align="center" valign="top">4.9 <br>(48)</td>
<td align="center" valign="top">3.0 <br>(40)</td>
<td align="center" valign="top">8.7 <br>(91)</td>
<td align="center" valign="top">2.6 <br>(30)</td>
<td align="center" valign="top">6.5 <br>(67)</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Bold">AUC<span class="Sub">0-t</span></span> (ng∙h/mL)</td>
<td align="center" valign="top">14531 <br>(47)</td>
<td align="center" valign="top">20683 <br>(41)</td>
<td align="center" valign="top">19836 <br>(40)</td>
<td align="center" valign="top">20482 <br>(37)</td>
<td align="center" valign="top">23797 <br>(45)</td>
<td align="center" valign="top">24340 <br>(48)</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">
<span class="Bold">AUC<span class="Sub">∞</span></span> (ng∙h/mL)</td>
<td align="center" valign="top">15045 <br>(46)</td>
<td align="center" valign="top">20833 <br>(41)</td>
<td align="center" valign="top">20490 <br>(39)</td>
<td align="center" valign="top">20815 <br>(37)</td>
<td align="center" valign="top">24194 <br>(44)</td>
<td align="center" valign="top">24704 <br>(47)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4ccf6c5f-b3ec-4289-b6ca-5e129acde24a"></a><a name="section-2.2.4.2"></a><p></p>
<h4><span class="Bold"><span class="Italics">Gender:</span></span></h4>
<p class="First">The effect of gender on the pharmacokinetics of metaxalone was assessed in an open label study, in which 48 healthy adult volunteers (24 males, 24 females) were administered two SKELAXIN 400 mg tablets (800 mg) under fasted conditions. The bioavailability of metaxalone was significantly higher in females compared to males as evidenced by C<span class="Sub">max</span> (2115 ng/mL <span class="Italics">versus</span> 1335 ng/mL) and AUC<span class="Sub">∞</span> (17884 ng∙h/mL <span class="Italics">versus</span> 10328 ng∙h/mL). The mean half-life was 11.1 hours in females and 7.6 hours in males. The apparent volume of distribution of metaxalone was approximately 22% higher in males than in females, but not significantly different when adjusted for body weight. Similar findings were also seen when the previously described combined dataset was used in the analysis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f96c91a6-4890-4634-81cc-5abbd49265d0"></a><a name="section-2.2.4.3"></a><p></p>
<h4><span class="Bold"><span class="Italics">Hepatic/<span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span>:</span></span></h4>
<p class="First">The impact of hepatic and <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> on the pharmacokinetics of metaxalone has not been determined. In the absence of such information, SKELAXIN should be used with caution in patients with hepatic and/or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_491f613c-6a2e-4d0f-8991-3559d07e805a"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">SKELAXIN (metaxalone) is indicated as an adjunct to rest, physical therapy, and other measures for the relief of <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomforts</span> associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Metaxalone does not directly relax <span class="product-label-link" type="condition" conceptid="4136244" conceptname="Feeling tense">tense</span> skeletal muscles in man. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_71e60d15-8a82-4029-8835-6f968f4411f8"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any components of this product.</p>
<p>Known tendency to drug induced, hemolytic, or other <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemias</span>. </p>
<p>Significantly impaired renal or hepatic function.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_d1feb559-666a-4193-86e5-16a63565834f"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">SKELAXIN may enhance the effects of alcohol and other CNS depressants.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_30c31ae8-0529-4f06-a94e-a4ac2359858d"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Metaxalone should be administered with great care to patients with pre-existing <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span>. Serial liver function studies should be performed in these patients.</p>
<p>False-positive Benedict's tests, due to an unknown reducing substance, have been noted. A glucose-specific test will differentiate findings. </p>
<p>Taking SKELAXIN with food may enhance general <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>; elderly patients may be especially susceptible to this CNS effect. (See <span class="Bold"><a href="#i4i_clinical_pharmacology_id_89f638c3-eb67-4adf-b18d-5279b897ebc5">CLINICAL PHARMACOLOGY</a>:</span><span class="Bold"><a href="#i4i_pharmacokinetics_id_7829cc73-cf47-481b-8aaa-e5ae6bcf4be6">Pharmacokinetics</a></span> and <span class="Bold"><a href="#i4i_precautions_id_30c31ae8-0529-4f06-a94e-a4ac2359858d">PRECAUTIONS:</a> <a href="#i4i_info_patients_id_c696a656-092d-4500-a2ad-fcd6d8d3143f">Information for Patients</a></span> ).</p>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_c696a656-092d-4500-a2ad-fcd6d8d3143f"></a><a name="section-6.1"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">SKELAXIN may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle, especially when used with alcohol or other CNS depressants. </p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_27d49665-7c26-4d36-914d-21a36473ffe4"></a><a name="section-6.2"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">The sedative effects of SKELAXIN and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive.  Therefore, caution should be exercised with patients who take more than one of these CNS depressants simultaneously.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_d561abbb-7338-447b-9246-3464b49f1cc4"></a><a name="section-6.3"></a><p></p>
<h2><span class="Bold"><span class="Italics">Carcinogenesis, Mutagenesis, Impairment of Fertility</span></span></h2>
<p class="First">The carcinogenic potential of metaxalone has not been determined.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_d469fe24-c991-45e0-bae6-937979d3250c"></a><a name="section-6.4"></a><p></p>
<h2><span class="Italics"><span class="Bold">Pregnancy</span></span></h2>
<p class="First">Reproduction studies in rats have not revealed evidence of impaired fertility or harm to the fetus due to metaxalone. Post marketing experience has not revealed evidence of fetal injury, but such experience cannot exclude the possibility of infrequent or subtle damage to the human fetus. Safe use of metaxalone has not been established with regard to possible adverse effects upon fetal development. Therefore, metaxalone tablets should not be used in women who are or may become pregnant and particularly during early pregnancy unless, in the judgement of the physician, the potential benefits outweigh the possible hazards. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_caf32a6a-4f7b-42dd-a4f3-15066aafebc3"></a><a name="section-6.5"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is secreted in human milk. As a general rule, nursing should not be undertaken while a patient is on a drug since many drugs are excreted in human milk. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_3275a905-8dff-4e3b-a5cb-6984bd3d4f58"></a><a name="section-6.6"></a><p></p>
<h2><span class="Bold"><span class="Italics">Pediatric Use</span></span></h2>
<p class="First">Safety and effectiveness in children 12 years of age and below have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_123d7438-3f77-495a-8236-008a26e9cd86"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The most frequent reactions to metaxalone include:</p>
<p>CNS: <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span> or "<span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>";</p>
<p>Digestive: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">gastrointestinal upset</span>.</p>
<p>Other adverse reactions are: </p>
<p>Immune System: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> with or without <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>; </p>
<p>Hematologic: <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>; <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>; </p>
<p>Hepatobiliary: <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>. </p>
<p>Though rare, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have been reported with metaxalone.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_3a6f1f97-6c4c-4340-a1ea-ebc20a2b5e11"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> by deliberate or accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> have occurred with metaxalone, particularly in combination with antidepressants, and have been reported with this class of drug in combination with alcohol. </p>
<p>When determining the LD<span class="Sub">50</span> in rats and mice, progressive sedation, hypnosis, and finally <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span> were noted as the dosage increased. In dogs, no LD<span class="Sub">50</span> could be determined as the higher doses produced an emetic action in 15 to 30 minutes. </p>
<p><span class="Italics">Treatment</span> - Gastric lavage and supportive therapy. Consultation with a regional poison control center is recommended.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_257ec2b3-a088-48ce-8224-f62fd98f7cea"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dose for adults and children over 12 years of age is one 800 mg tablet three to four times a day. </p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_1617092b-436b-4ae4-a3f2-814825e97ec5"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">SKELAXIN (metaxalone) is available as an 800 mg oval, scored pink tablet inscribed with 8667 on the scored side and "S" on the other. Available in bottles of 100 (<span class="Bold">NDC</span> 60793-136-01) and in bottles of 500 (<span class="Bold">NDC</span> 60793-136-05). </p>
<p>Store at Controlled Room Temperature, between 15°C and 30°C (59°F and 86°F). </p>
<p><span class="Bold">Rx Only</span></p>
<p>Prescribing Information as of April 2008.</p>
<p>Distributed by: King Pharmaceuticals, Inc., Bristol, TN 37620</p>
<p>Manufactured by: Corepharma LLC, Middlesex, NJ 08846</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_fb2ee4be-bdc8-48a0-a409-c24400a4df20"></a><a name="section-11"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 100 Tablet Bottle Label</h1>
<p class="First">SEALED FOR YOUR PROTECTION</p>
<p><span class="Bold Italics">Pfizer</span><br>NDC 60793-136-01</p>
<p><span class="Bold">Skelaxin</span><span class="Sup">®</span><br>(metaxalone)</p>
<p><span class="Bold">800 mg</span></p>
<p>100 Tablets<br><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 100 Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7a4163f2-c553-4d14-7e98-d14c5c7f772a&amp;name=skelaxin-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SKELAXIN 		
					</strong><br><span class="contentTableReg">metaxalone tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60793-136</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METAXALONE</strong> (METAXALONE) </td>
<td class="formItem">METAXALONE</td>
<td class="formItem">800 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">20mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">8667;S</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60793-136-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:60793-136-05</td>
<td class="formItem">500  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA013217</td>
<td class="formItem">08/30/2002</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Pfizer Laboratories Div Pfizer Inc
							(134489525)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">CorePharma, LLC</td>
<td class="formItem"></td>
<td class="formItem">031192276</td>
<td class="formItem">ANALYSIS(60793-136), LABEL(60793-136), MANUFACTURE(60793-136), PACK(60793-136)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a4c8c2fd-e077-442e-bf82-f16034fb580f</div>
<div>Set id: 7a4163f2-c553-4d14-7e98-d14c5c7f772a</div>
<div>Version: 5</div>
<div>Effective Time: 20140411</div>
</div>
</div> <div class="DistributorName">Pfizer Laboratories Div Pfizer Inc</div></p>
</body></html>
